UFCW Local 1500 Welfare Fund v. Johnson & Johnson and Janssen Biotech

Updated: October 30, 2017
Status: Ongoing Case

On October 27, 2017, Labaton Sucharow filed a class action complaint on behalf of UFCW Local 1500 Welfare Fund against Johnson & Johnson and Janssen Biotech, Inc. (collectively, J&J) for claims under federal and state antitrust laws and state consumer protection laws.

The plaintiff seeks to recover damages and obtain injunctive and equitable relief for the substantial injuries it and others similarly situated have sustained arising from J&J’s anticompetitive scheme to abuse its monopoly power, exclude competition, and raise prices for Remicade®, a biologic medication used to treat chronic illnesses such as rheumatoid arthritis, plaque psoriasis, and Crohn’s disease. 

The case is UFCW Local 1500 Welfare Fund v. Johnson & Johnson and Janssen Biotech, Inc., No. 17-cv-04830 (E.D. Pa.). Labaton Sucharow represents the plaintiff UFCW Local 1500 Welfare Fund. The defendants are Johnson & Johnson and Janssen Biotech, Inc.

Case Materials

Complaint